Clinical Trial Update: Clinical Usefulness and Influence on Esophageal Motility of Pyridostigmine for Dysphagia in Systemic Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 trial of pyridostigmine for dysphagia in systemic sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Pyridostigmine (pyridostigmine)

Snippet

Sponsor: Universitair Ziekenhuis Brussel | Conditions: Systemic Sclerosis With Dysphagia | Phase 2 | Status: WITHDRAWN